Growth hormone (GH) treatment in GH-deficient adults: Effects on muscle size, strength and neural activation

A. Sartorio, M. V. Narici

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The effects of 6 months of recombinant growth hormone (GH) treatment (0.5 IU kg-1 per week) on muscle size, strength and neural activation (EMG) was studied in eight adults with childhood onset GH deficiency (GHD). Before treatment, height, body mass (BM) and lean body mass (LBM) of the GHD subjects were significantly lower (P2 was found between the two groups. By contrast, LLV(M+B)/height3 was 82.0±19.0% that of the controls (P3 of the GHD patients after treatment was no longer significantly different from that of the controls. Quadriceps MVC increased by 9.8±12.0% (P

Original languageEnglish
Pages (from-to)527-537
Number of pages11
JournalClinical Physiology
Volume14
Issue number5
Publication statusPublished - 1994

Fingerprint

Muscle Strength
Growth Hormone
Body Height
Therapeutics

Keywords

  • GH deficiency
  • Growth hormone
  • Hypopituitarism
  • Muscle cross-sectional area
  • Muscle strength

ASJC Scopus subject areas

  • Physiology

Cite this

Growth hormone (GH) treatment in GH-deficient adults : Effects on muscle size, strength and neural activation. / Sartorio, A.; Narici, M. V.

In: Clinical Physiology, Vol. 14, No. 5, 1994, p. 527-537.

Research output: Contribution to journalArticle

@article{d47189c6da024ea2b916b74bb50f5585,
title = "Growth hormone (GH) treatment in GH-deficient adults: Effects on muscle size, strength and neural activation",
abstract = "The effects of 6 months of recombinant growth hormone (GH) treatment (0.5 IU kg-1 per week) on muscle size, strength and neural activation (EMG) was studied in eight adults with childhood onset GH deficiency (GHD). Before treatment, height, body mass (BM) and lean body mass (LBM) of the GHD subjects were significantly lower (P2 was found between the two groups. By contrast, LLV(M+B)/height3 was 82.0±19.0{\%} that of the controls (P3 of the GHD patients after treatment was no longer significantly different from that of the controls. Quadriceps MVC increased by 9.8±12.0{\%} (P",
keywords = "GH deficiency, Growth hormone, Hypopituitarism, Muscle cross-sectional area, Muscle strength",
author = "A. Sartorio and Narici, {M. V.}",
year = "1994",
language = "English",
volume = "14",
pages = "527--537",
journal = "Clinical Physiology",
issn = "0144-5979",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Growth hormone (GH) treatment in GH-deficient adults

T2 - Effects on muscle size, strength and neural activation

AU - Sartorio, A.

AU - Narici, M. V.

PY - 1994

Y1 - 1994

N2 - The effects of 6 months of recombinant growth hormone (GH) treatment (0.5 IU kg-1 per week) on muscle size, strength and neural activation (EMG) was studied in eight adults with childhood onset GH deficiency (GHD). Before treatment, height, body mass (BM) and lean body mass (LBM) of the GHD subjects were significantly lower (P2 was found between the two groups. By contrast, LLV(M+B)/height3 was 82.0±19.0% that of the controls (P3 of the GHD patients after treatment was no longer significantly different from that of the controls. Quadriceps MVC increased by 9.8±12.0% (P

AB - The effects of 6 months of recombinant growth hormone (GH) treatment (0.5 IU kg-1 per week) on muscle size, strength and neural activation (EMG) was studied in eight adults with childhood onset GH deficiency (GHD). Before treatment, height, body mass (BM) and lean body mass (LBM) of the GHD subjects were significantly lower (P2 was found between the two groups. By contrast, LLV(M+B)/height3 was 82.0±19.0% that of the controls (P3 of the GHD patients after treatment was no longer significantly different from that of the controls. Quadriceps MVC increased by 9.8±12.0% (P

KW - GH deficiency

KW - Growth hormone

KW - Hypopituitarism

KW - Muscle cross-sectional area

KW - Muscle strength

UR - http://www.scopus.com/inward/record.url?scp=0027934869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027934869&partnerID=8YFLogxK

M3 - Article

C2 - 7820977

AN - SCOPUS:0027934869

VL - 14

SP - 527

EP - 537

JO - Clinical Physiology

JF - Clinical Physiology

SN - 0144-5979

IS - 5

ER -